O GoConqr está de visual novo! Conte para nós o que você achou.

Flashcards

DI Exam 2

Lauren Pattah Pharmacy Inglês 124 flashcards

DI Exam 2

Flashcards do conjunto (124)

  1. 1What is professional writing?A writing is considered professional when a professional takes pen, pencil, word processor, or any other writing implement in hand to fulfill professional duties
  2. 2What is the purpose of professional writing?Purpose is to inform, instruct, persuade or entertain
  3. 3What are some examples of professional writing?Journal article
    Review article
    Book chapters
    P&T drug evaluation
    Policy and procedures for institutions
    Final evaluation
    Slide or poster presentation
    Letter of recommendation
    Documentation in patient chart
  4. 4What are the advantages of professional writing?Promotion (Annual evaluation tool)
    Scholarship in academia
    Share ideas, knowledge, and best practices
    Gratification and satisfaction
    Recognition in the field
  5. 5What are some disadvantages of professional writing?Time investment (Practice and revisions)
    Criticism (Possible rejection)
    Pay to publish
  6. 6What are the 8 steps of writing?What are the 8 steps of writing?
  7. 7What are some simple rules?Know your purpose
    Organize your thoughts
    Put yourselves in readers position
    Use words correctly and carefully
    Edit/revise your work
  8. 81. Purpose1. Purpose
  9. 92. Authorship2. Authorship
  10. 103. Know Your Audience3. Know Your Audience
  11. 114. Writing Style4. Writing Style
  12. 12Writing style continuedWriting style continued
  13. 134a. Writing a Document4a. Writing a Document
  14. 144a. Writing a Document- Introduction4a. Writing a Document- Introduction
  15. 154a. Writing a Document- Body4a. Writing a Document- Body
  16. 164a. Writing a Document - Conclusion4a. Writing a Document - Conclusion
  17. 17General Rules of WritingGeneral Rules of Writing
  18. 18General Rules of Writing – continuedGeneral Rules of Writing – continued
  19. 19Specific Rules of WritingSpecific Rules of Writing
  20. 20Specific Rules of Writing - continuedSpecific Rules of Writing - continued
  21. 21Specific Rules of Writing - continuedSpecific Rules of Writing - continued
  22. 22Specific Rules of Writing - continuedSpecific Rules of Writing - continued
  23. 23What is plagarism?What is plagarism?
  24. 24What are the two types of plagarism?What are the two types of plagarism?
  25. 25What are some disciplinary actions for plagarising?Warning
    Probation
    Suspension
    Dismissal
  26. 26How can you Avoid Plagiarism?How can you Avoid Plagiarism?
  27. 27Copyright and Fair UseCopyright and Fair Use
  28. 28How to Avoid Copyright ViolationsHow to Avoid Copyright Violations
  29. 29References/CitationReferences/Citation
  30. 30Citing a Journal ArticleCiting a Journal Article
  31. 31Citing a Journal Article - continuedCiting a Journal Article - continued
  32. 32Next Steps5. Submission to a journal
    6. Peer review
    7. Revision
    8. Galley proofs
  33. 33NewsletterNewsletter
  34. 34PresentationPresentation
  35. 35Platform PresentationPlatform Presentation
  36. 36Platform Presentation - continuedPlatform Presentation - continued
  37. 37Platform Presentation - continuedPlatform Presentation - continued
  38. 38Poster PresentationPoster Presentation
  39. 39Drug Information ResponseDrug Information Response
  40. 40In conclusion…Keep the general and specific writing rules in mind
    Adhere to publisher’s guidelines
    Provide proper citation to avoid copyright infringements or plagiarism
  41. 41What are the steps to a DI question?What are the steps to a DI question?
  42. 42Other Pertinent FactorsOther Pertinent Factors
  43. 43Analysis and SynthesisAnalysis and Synthesis
  44. 44Key characteristics of a responseTimely (based on acuity and expectations)
    Concise yet complete
    Evidence-based
    Objective, balanced, unbiased
  45. 45How could a DI response NOT be evidence-based or objective?You use your own clinical experience. “Im a cardiologist, I always see patients with hypertension… etc” But if there is evidence available, you should be relying on that
  46. 46General format for a responseGeneral format for a response
  47. 47Follow-UpFollow-Up
  48. 48What is important during the call with the health care professional?Patient-specific information DURING THE CALL/REQUEST is
    important for a professional, timely response
  49. 49Key features of an effective DI responseKey features of an effective DI response
  50. 50Key features of an effective DI responseKey features of an effective DI response
  51. 51Key features of an effective DI responseKey features of an effective DI response
  52. 52Step-wise approach for providing a drug information responseStep-wise approach for providing a drug information response
  53. 531. Restating the question1. Restating the question
  54. 542. Brief summary of findings2. Brief summary of findings
  55. 553. In-depth review3. In-depth review
  56. 56Written versus Verbal responseWritten versus Verbal response
  57. 57Written response – best practicesWritten response – best practices
  58. 58Verbal response - best practicesVerbal response - best practices
  59. 594. Offer additional assistance4. Offer additional assistance
  60. 605. Follow-up5. Follow-up
  61. 61Formulary & Formulary SystemFormulary & Formulary System
  62. 62What and where are formularies?According to ASHP, the formulary listing is only a part of the picture. The formulary also includes the Med use policies that guide practice as well as the decision-support, and drug guidelines that are available in a health-system
    When we talk about the formulary system, here we’re referring to the PROCESS in which the healthcare organization through MD, RPH and other health care professionals establishes the P&P regarding drugs tx and products. And therapies and identified drug products and therapies that are most medically appropriate and cost-effective to best serve the health interests of a given population.
    Where are they: hospitals, acute care, Government, Medicare and Medicaid, VA, Insurance, and Managed Care. –for purposes of this talk, we’ll focus on the hospital
  63. 63Formulary Systems: Where do you find them?Hospitals
    Medicare/Medicaid
    Pharmacy Benefit Managers (PBM)
    Managed care
  64. 64Open versus Closed FormulariesOpen versus Closed Formularies
  65. 65What is an example of an open vs closed formulary?AN example, say a patient is admitted on a non-formulary med. While there would be other meds in the same class, it may be best to allow the NF product rather than adding another complicating factor to the hospital’s treatment.
  66. 66Pharmacy & Therapeutics CommitteePharmacy & Therapeutics Committee
  67. 67Pharmacy & Therapeutics Committee StructurePharmacy & Therapeutics Committee Structure
  68. 68P&T Committee is made of _____.P&T Committee is made of reps of medical staff, administration, pharmacy, nursing, medical records, risk management, quality assurance, risk management, and any professions medications include (anesthesia, dietary-food & nutrition, surgery etc).
  69. 69Organizational Structure of P&T in HospitalsOrganizational Structure of P&T in Hospitals
  70. 70P&T Adhoc CommitteesP&T Adhoc Committees
  71. 71P&T - Conflict of InterestP&T - Conflict of Interest
  72. 72Pharmacist’s role on P&TPharmacist’s role on P&T
  73. 73P&T FunctionsP&T Functions
  74. 74What do P&T functions include?P&T functions include- determining which drugs are available (the formulary)
    And any drug-related P&P including: who can prescribe specific drugs, how non-formulary drugs are handled, development of ordersets and drug guidelines.
    And a big focus of P&T is quality assurance- specifically the focus is on patient outcomes and not solely on cost.
  75. 75P&T Formulary ManagementP&T Formulary Management
  76. 76So How are medications requested and reviewed for addition/deletion from the formulary?This process need to be structured.
    Physician generally contacts the RPh to see if they can get a drug on formulary and there is a form that they must complete. I’ll show you what needs to be included in the next slide. The evaluation of the drug for formulary involves many aspects which we’ll review and ultimately, the eval goes to the P&T for review. The P&T review at committee generally involves a pharmacist presenting some part of the drug request. Some ask the physician to presents the request in conjunction with the pharmacist.
    Once the drug is reviewed at the committee, it is either approved (either with restriction or a drug-guideline) or it is rejected.
  77. 77Formulary Management: Additions Drug Request FormFormulary Management: Additions Drug Request Form
  78. 78What are items that are generally found on a request for formulary addition?Date and/time—this is included because behind the scenes, there’s a great deal of work that goes on even to be considered. --most hospitals restrict drug requests to come ONLY from the MD.
    Name of drug: brand and generic
    Drug Info: Dosage Forms and Strength, Therapeutic Class, Principal Indications:
    Anticipated Use: Population, pediatrics, geriatrics, or specific
    Please indicate the approximate number of patients per month that will be treated with this drug
    Please indicate patient population the drug would be used in:
    Neonatal  Pediatric  Adolescent  Adult  Geriatric
    Why it’s needed: What are the significant benefits/advantages (including cost) of the requested drug compared with the comparable products/procedures listed above?
    Formulary changes: List any drugs, therapies, or procedures currently available on the Formulary that are comparable or similar to the requested drug.
    If the requested drug(s) were approved for addition to the formulary, which current formulary agent(s) would decrease in hospital.
  79. 79Formulary Management Types of P&T Drug ReviewsFormulary Management Types of P&T Drug Reviews
  80. 80P&T Drug Reviews: New Drug MonographsP&T Drug Reviews: New Drug Monographs
  81. 81P&T Drug Review: Financial AnalysisP&T Drug Review: Financial Analysis
  82. 82P&T Drug Review: SafetyP&T Drug Review: Safety
  83. 83Institute for Safe Medication Practices (ISMP) ismp.orgInstitute for Safe Medication Practices (ISMP) ismp.org
  84. 84P&T Drug Review Safety: FMEAP&T Drug Review Safety: FMEA
  85. 85P&T Drug Review: Drug Class ReviewsJoint Commission: All formulary medications are to be reviewed at least annually.
    Includes ALL agents (formulary/non-formulary)
    May lead to removal, guidelines or drug restrictions
    May lead to removal of redundant agents, or restrictions or guideline additions.
  86. 86Drug Re-evaluation & Expedited Review: In most cases, this might be that the drug is just newly released in a new dosage form (say different strength capsule/tablet). But in some cases there could be new information that is released that warrants the drug being looked at. (this might be that it has a new black box, or that it has a specific indication that was newly studied or in some cases, there may be cost data that is relevent.Drug Re-evaluation & Expedited Review: In most cases, this might be that the drug is just newly released in a new dosage form (say di...
  87. 87Managing Medication Use StrategiesGeneric Drugs
    Non-formulary drug request
    Therapeutic Interchange
    Guided-Use
    Guidelines
    MUE
  88. 88Generic DrugsGeneric Substitution
    FDA bioequivalent products
    Doesn’t require P&T approval if FDA approved
    However in some states law, or local P&P may prohibit substitution (e.g. narrow therapeutic index-anticoagulants, anticonvulsants)
    P&P must allow: MD to opt-out if clinically justified
  89. 89Non-Formulary RequestsNon-Formulary Requests
  90. 90Therapeutic InterchangeTherapeutic Interchange
  91. 91Therapeutic Interchange: Common ExamplesH2 Antagonists: famotidine-ranitidine-cimetidine
    Proton Pump Inhibitors: omeprazole-esomeprazole
    Statins: simvastatin-lovastatin-rosuvastatin
    Quinolones: ciprofloxacin-moxifloxacin-levofloxacin
    IV to PO
  92. 92Guided Use Examples: Drug Approval + RestrictionGuided Use Examples: Drug Approval + Restriction
  93. 93Drug Approval and RestrictionPatients need to meet a specific criteria before you dispense the drug. (there needs to be a process in case the patient doesn’t meet the criteria but is still medically necessary). This is also a strategy when drugs are on shortage. An example of this is a drug Vaprisol or Conivaptan (that is very costly and is used for hyponatremia)
    Some drugs must be approved by a specific service or those with specific training before you dispense it. This is the case when the drug poses a serious threat if not used correctly (Xigris- an agent used for sepsis, for example must receive the ID attending’s approval before being dispensed. OR a specific chemo agent that can only be prescribed by an oncologist.
    Limiting to specific areas. This may be because the drug needs specific equipment to be used. Like a neuromuscular blocker in an ICU setting.
    Approval of a medical director. –this might be for very high cost agents when you see that there’s very little role but the MD wants to use the drug non-formulary
  94. 94Clinical Practice GuidelinesEvidence-Based
    Decrease variability in practice
    Reduce costs
    Improve patient outcomes
    Examples: Anticoagulation use-heparin, Renal dosing, Aminoglycosides
    Clinical practice guidelines are another tool in managing medication use that can ensure medications are used appropriately.
  95. 95Order Set DevelopmentOrder Set Development
  96. 96Order SetP&T responsible for overseeing all medication-related use
    Reducing variability, chance for error, and cost.
    May contain non-formularies if they are not updated
    Should be reviewed on a periodic basis (annually) to ensure they keep up with practice, P&P and the formulary
  97. 97Medication Use Evaluation (MUE)Evidence-based
    Focus: Quality Improvement
    Any part of medication use process (Problem-prone high-risk, high-cost medications)
    Paper/EMR
    Accreditation
    MUE, is a way to systematically review a medication in the organization again with evidence based criteria.
    Although some have referred to these as Drug use evals, or reviews, they are all systematic, and using a quality improvement approach.
    Can be as simple a finding out what common doses are used of an specific drug to a complex look at the specific prescribing protocol.
    Joint Commission requires MUE as a component of the medication management system
    ASHP guidelines dictate how this is conducted.
  98. 98Example MUEExample MUE
  99. 99P&T Medication Policies and ProceduresAs needed PRN medications
    Automatic stop/resume medications
    Patient’s Own Medications
    Self-administered medications
    Medication-related devices (pumps)
    Drug Samples
    Investigational medications
    Discharge medications
  100. 100Drug ShortagesDrug Shortages
  101. 101P&T EducationInservices
    Grand rounds
    Pharmacist ->MD education during prescribing/dispensing
    Staff meetings
    Email
    Newsletters
    Mailings
    Prescriber detailing
    Pharmacy/Hospital websites
  102. 102What is a medication error?What is a medication error?
  103. 103Adverse Drug Event (ADE)Adverse Drug Event (ADE)
  104. 104Adverse Drug Reaction (ADR)Adverse Drug Reaction (ADR)
  105. 105ASHP Definition of an ADRASHP Definition of an ADR
  106. 106ME, ADE and ADRME, ADE and ADR
  107. 107Incidence and Mortality10-20% of hospitalized experience an ADR
    20% of ambulatory patients experience an ADR
    ADRs accounts for 5-10% of hospital admissions
    ADRs cause between 40,000 and 100,000 deaths/year
    About 50% of ADRs are considered preventable!
  108. 108Impact of ADRsPatients lose confidence in health care practitioners
    Patients may refuse to try other treatment options based on previous experience
    Patients may seek self-care which can result in further ADRs
    Annual cost estimated to be 5-7 billion dollars/year
  109. 109PharmacovigilancePharmacovigilance
  110. 110Post-Marketing ADR ExamplePost-Marketing ADR Example
  111. 111Classification of ADRsClassification of ADRs
  112. 112Severity of ADRsSeverity of ADRs
  113. 113Identifying ADRsIdentifying ADRs
  114. 114ADR Indicator DrugsADR Indicator Drugs
  115. 115Causality and ProbabilityCausality and Probability
  116. 116Assessing Probability/CausalityAssessing Probability/Causality
  117. 117Assessing Probability/CausalityAssessing Probability/Causality
  118. 118Naranjo Probability ScaleNaranjo Probability Scale
  119. 119Naranjo Probability Scale (cont)Naranjo Probability Scale (cont)
  120. 120At-Risk PopulationsAt-Risk Populations
  121. 121MedWatch and FAERSMedWatch and FAERS
  122. 122Additional ResourcesAdditional Resources
  123. 123Preventing ADRsPreventing ADRs
  124. 124SummarySummary

Informações

Descrição
Pharmacy FlashCards sobre DI Exam 2 , criado por Lauren Pattah em 12-10-2016.
Criado por
Lauren Pattah
Visualizações
2
Avaliação

Fale Conosco

Sobre o que é sua mensagem?

O que você acha do novo visual?

Você gostou?